Pharnext SA

07/12/2021 | Press release | Distributed by Public on 07/12/2021 00:10

Pharnext Announces First Patient Enrolled in Europe in the PREMIER Trial, its Pivotal Phase III Clinical Study of PXT3003 in Charcot-Marie-Tooth Disease Type 1A ('CMT1A')